DEPARTMENT OF DEFENSE
ARMED FORCES EPIDEMIOLOGICAL BOARD
5109 LEESBURG PIKE
FALLS CHURCH, VA 22041-3258

AFEB (15-1a) 94-7 03 August 1994

MEMORANDUM FOR THE ASSISTANT SECRETARY OF DEFENSE (HEALTH AFFAIRS)

SUBJECT: Biological Warfare Vaccines

In accordance with DoD Directive 6205.3, the Armed Forces Epidemiological Board (AFEB) met on 3 August 1994 to review two vaccines available to protect against validated biological warfare threat agents and makes the following recommendations:

a. **THE LICENSED ANTHRAX VACCINE IS SUITABLE FOR USE IN PERSONNEL ASSIGNED, PRE-DESIGNATED OR SCHEDULED FOR DEPLOYMENT TO AREAS WITH A VALIDATED HIGH THREAT UNDER ITS APPROVED INSTRUCTIONS.**

b. **THE INVESTIGATIONAL BOTULINUM TOXOID VACCINE IS SUITABLE FOR USE UNDER THE CURRENT PROTOCOL IN PERSONNEL WITH RISK AS DEFINED ABOVE. THE BOARD STRONGLY ENCOURAGES PURSUIT OF FDA APPROVAL OF THIS PRODUCT.**

FOR THE ARMED FORCES EPIDEMIOLOGICAL BOARD:

LEWIS H. KULLER, M.D., DrPH
President, AFEB

MICHAEL R. PETERSON, DVM, MPH, DrPH
Colonel, USAF, BSC
Executive Secretary

CF: CO, USAMRDALC